Wednesday, December 23, 2015 7:22:57 AM
Piper Jaffray analyst Joshua Schimmer views Celgene's settlement with Natco for the Revlimid Paragraph IV patent challenge as "creative and a positive." The news removes the overhang that allows the company to continue managing towards 25% annual earnings growth through the middle of the next decade, Schimmer tells investors in a research note. The agreement allows a limited generic launch in 2022, the analyst points out. Celgene remains one of his top biotech picks with an Overweight rating and $163 price target
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM